Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 7/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | USP2 | O75604 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | PDE4A | P27815 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | PDE2A | O00408 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | PDE5A | O76074 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445842 | 0.89 | PDE10A (0.81) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| SCHEMBL21611898 | 0.87 | PDE10A (0.77) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29360983 | 0.87 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL34702 | 0.87 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29387160 | 0.87 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| SCHEMBL11845148 | 0.87 | PDE10A (0.77) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL9551009 | 0.87 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| SCHEMBL1445847 | 0.86 | PDE10A (0.75) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Hydrochloric Acid SCHEMBL21611897 | 0.86 | PDE10A (0.75) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL677440 | 0.86 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038239-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2004-02-26 | — | — | US | claimed |
| EP-1300464-A1 | FUNGAL CELL WALL SYNTHESIS GENE | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | claimed |
| US-20210163453-A1 | DERIVATIVES OF PAPAVERINE THAT ARE EFFECTIVE HYPOXIC TUMOR RADIOSENSITIZERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-03 | — | — | US | disclosed |
| WO-2020023537-A1 | DERIVATIVES OF PAPAVERINE THAT ARE EFFECTIVE HYPOXIC TUMOR RADIOSENSITIZERS | OHIO STATE INNOVATION FOUNDATION (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7897387-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20090325228-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090117586-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090098636-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT CO., LTD (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20080261272-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-10-23 | — | — | US | disclosed |
| US-20080166765-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT, LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-7375204-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060234283-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20060234349-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20040038239-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1300464-A1 | FUNGAL CELL WALL SYNTHESIS GENE | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325228-A1 | FUNGAL CELL WALL SYNTHESIS GENE | ERG28, GPI, DPM1 | PDE10A 2142/4885PDE3A 2126/4885PDE3B 2130/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | PDE10A 159/4885PDE3A 49/4885PDE3B 55/4885 |
| US-20040038239-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | PDE10A 2142/4885PDE3A 2126/4885PDE3B 2130/4885 |
| US-20080166765-A1 | FUNGAL CELL WALL SYNTHESIS GENE | ERG28, GPI, DPM1 | PDE10A 2241/4885PDE3A 2298/4885PDE3B 2320/4885 |
| US-20060234349-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | PDE10A 2142/4885PDE3A 2126/4885PDE3B 2130/4885 |
| US-20210163453-A1 | DERIVATIVES OF PAPAVERINE THAT ARE EFFECTIVE HYPOXIC TUMOR RADIOSENSITIZERS | HIF1AN, HIF1A, HYOU1 | PDE10A 590/4885PDE3A 266/4885PDE3B 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.